bird-flu-stocks-logo
birdflustocks.com
Vir Biotechnology: VIR-2482 phase 2 study failed, stock drops 44%
birdflustocks.com » bird flu stocks  »  Vir Biotechnology: VIR-2482 phase 2 study failed, stock drops 44%
Vir Biotechnology: VIR-2482 phase 2 study failed, stock drops 44%
July 20, 2023

https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-announces-topline-data-phase-2-peninsula-trial